FGP
AXSM icon

Freestone Grove Partners’s Axsome Therapeutics AXSM Stock Holding History

Freestone Grove Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,887
Closed -$319K – 1029
2026
Q1 		$319K Buy
+1,887
New +$326K ﹤0.01% 679
2025
Q4 		– Sell
-2,494
Closed -$303K – 737
2025
Q3 		$303K Buy
+2,494
New +$281K ﹤0.01% 612

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Freestone Grove Partners's AXSM Position: Q2 2026 in Review

Freestone Grove Partners sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 1,887 shares — an estimated $319K sold.

Freestone Grove Partners first reported a position in AXSM in Q3 2025 and held it in 2 quarters. The position peaked at $319K in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Freestone Grove Partners reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 1,887 Axsome Therapeutics shares in Q2 2026, an estimated $319K.
  • Freestone Grove Partners first reported a position in Axsome Therapeutics in Q3 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Axsome Therapeutics position peaked at $319K in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.